LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Martínez-Silva, María G"
  2. AU="Christino, Melissa A"
  3. AU="Silva, Larissa L"
  4. AU="Tonks, Michael R."
  5. AU="Korhonen, H"
  6. AU="Mukendi, John T"
  7. AU="Athira S. Raj"
  8. AU="Corbacho, Belen"
  9. AU="Andrei, Adin Cristian" AU="Andrei, Adin Cristian"
  10. AU="Erminia Donnarumma"
  11. AU="Albores-Figueroa, Rosenberg"
  12. AU="Squillace, Lino"
  13. AU="Laufs, Sebastian"
  14. AU="McCanny, Suzette"
  15. AU="McHardy, John Alexander"
  16. AU="Erdal, Ranya"
  17. AU="Li, Long-Xia"
  18. AU="Esapa, Benjamina"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel: A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival.

    Barrón-Gallardo, Carlos A / Garcia-Chagollán, Mariel / Morán-Mendoza, Andres J / Delgadillo-Cristerna, Raul / Martínez-Silva, María G / Villaseñor-García, María M / Aguilar-Lemarroy, Adriana / Jave-Suárez, Luis F

    Frontiers in genetics

    2022  Band 13, Seite(n) 991706

    Abstract: Breast cancer ranks first in terms of mortality and incidence rates worldwide among women. The HER2+ molecular subtype is one of the most aggressive subtypes; its treatment includes neoadjuvant chemotherapy and the use of a HER2 antibody. Some patients ... ...

    Abstract Breast cancer ranks first in terms of mortality and incidence rates worldwide among women. The HER2+ molecular subtype is one of the most aggressive subtypes; its treatment includes neoadjuvant chemotherapy and the use of a HER2 antibody. Some patients develop resistance despite positive results obtained using this therapeutic strategy.
    Objective: To identify prognostic markers for treatment and survival in HER2+ patients.
    Methods: Patients treated with neoadjuvant chemotherapy were assigned to sensitive and resistant groups based on their treatment response. Differentially expressed genes (DEGs) were identified using RNA-seq analysis. KEGG pathway, gene ontology, and interactome analyses were performed for all DEGs. An enrichment analysis Gene set enrichment analysis was performed. All DEGs were analyzed for overall (OS) and disease-free survival (DFS).
    Results: A total of 94 DEGs were related to treatment resistance. Survival analysis showed that 12 genes (ATF6B, DHRS13, DIRAS1, ERAL1, GRIN2B, L1CAM, IRX3, PRTFDC1, PBX2, S100B, SLC9A3R2, and TNXB) were good predictors of disease-free survival, and eight genes (GNG4, IL22RA2, MICA, S100B, SERPINF2, HLA-A, DIRAS1, and TNXB) were good predictors of overall survival (OS).
    Conclusion: We highlighted a molecular expression signature that can differentiate the treatment response, overall survival, and DFS of patients with HER2+ breast cancer.
    Sprache Englisch
    Erscheinungsdatum 2022-10-21
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2606823-0
    ISSN 1664-8021
    ISSN 1664-8021
    DOI 10.3389/fgene.2022.991706
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.

    Barrón-Gallardo, Carlos A / Garcia-Chagollán, Mariel / Morán-Mendoza, Andres J / Delgadillo-Cristerna, Raul / Martínez-Silva, María G / Aguilar-Lemarroy, Adriana / Jave-Suárez, Luis F

    Technology in cancer research & treatment

    2022  Band 21, Seite(n) 15330338211068965

    Abstract: Worldwide breast cancer ranks first in mortality and incidence rates in women over 20 years old. Rather than one disease, breast cancer is a heterogeneous group of diseases that express distinct molecular profiles. Neoadjuvant chemotherapy is an ... ...

    Abstract Worldwide breast cancer ranks first in mortality and incidence rates in women over 20 years old. Rather than one disease, breast cancer is a heterogeneous group of diseases that express distinct molecular profiles. Neoadjuvant chemotherapy is an important therapeutic strategy for breast cancer patients independently of their molecular subtype, with the drawback of resistance development. In addition, chemotherapy has adverse effects that combined with resistance could contribute to lower overall survival. Although great efforts have been made to find diagnostic and prognostic biomarkers for breast cancer and for response to targeted and immune therapy for this pathology, little has been explored regarding biomarkers of response to anthracyclines and taxanes based neoadjuvant chemotherapy. This work aimed to evaluate the molecular profile of patients who received neoadjuvant chemotherapy to identify differentially expressed genes (DEGs) that could be used as biomarkers of chemotherapy response and overall survival. Breast cancer patients who were candidates for neoadjuvant chemotherapy were enrolled in this study. After treatment and according to their pathological response, they were assigned as sensitive or resistant. To evaluate DEGs, Gene Ontology, Kyoto Encyclopedia Gene and Genome (KEGG), and protein-protein interactions, RNA-seq information from all patients was obtained by next-generation sequencing. A total of 1985 DEGs were found, and KEGG analysis indicated a great number of DEGs in metabolic pathways, pathways in cancer, cytokine-cytokine receptor interactions, and neuroactive ligand-receptor interactions. A selection of 73 DEGs was used further for an analysis of overall survival using the METABRIC study and the ductal carcinoma dataset of The Cancer Genome Atlas (TCGA) database. Nine DEGs correlated with overall survival, of which the subexpression of
    Mesh-Begriff(e) Biomarkers, Tumor ; Breast Neoplasms/diagnosis ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Cell Line, Tumor ; Clinical Decision-Making ; Computational Biology ; Disease Management ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Ontology ; Humans ; Neoadjuvant Therapy ; Prognosis ; Protein Interaction Mapping ; Transcriptome
    Chemische Substanzen Biomarkers, Tumor
    Sprache Englisch
    Erscheinungsdatum 2022-01-28
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2146365-7
    ISSN 1533-0338 ; 1533-0346
    ISSN (online) 1533-0338
    ISSN 1533-0346
    DOI 10.1177/15330338211068965
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5871: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Frecuencia de lesiones epiteliales cervicales reportadas en el Laboratorio Regional de Citología Exfoliativa de Jalisco.

    González-López, Sergio / Martínez-Silva, María G / Hernández-Hernández, Dulce M / Aguilar-Lemarroy, Adriana / Jave-Suárez, Luis Felipe

    Revista medica del Instituto Mexicano del Seguro Social

    2015  Band 53 Suppl 2, Seite(n) S132–9

    Abstract: Background: The Official Mexican Norm for the prevention, treatment and control of Cervical Cancer (CC) indicates that the Papanicolau (Pap) is the procedure for the detection of this neoplasia; therefore, it is of interest to know the prevalence of ... ...

    Titelübersetzung Frequency of cervical epithelial lesions reported in the Regional Laboratory of Exfoliative Cytology in Jalisco.
    Abstract Background: The Official Mexican Norm for the prevention, treatment and control of Cervical Cancer (CC) indicates that the Papanicolau (Pap) is the procedure for the detection of this neoplasia; therefore, it is of interest to know the prevalence of suspected cases by this technique in Mexican population. In this study, we show the diagnosed cases in the State of Jalisco, México.
    Methods: A retrospective study was made to the samples that arrived for their analysis to the Laboratorio Regional de Citología Exfoliativa (LARCE), of the Instituto Mexicano del Seguro Social (IMSS) in Guadalajara, Jalisco. We considered all cases from January 2010 to December 2012.
    Results: We analyzed 188 095 cases, from which 5.3 % had a diagnosis of low dysplasia, 0.18 % of moderated dysplasia and 0.05 % of high dysplasia. Microinvasive and invasive cancer showed a low frequency (0.03 %).
    Conclusions: The frequency of abnormal findings identified by vaginal cervical cytology is relatively low. The number of inadequate and limited samples for cytological assessment is high; there is a high proportion of women attending for the first time in life to cytology evaluation in older age groups.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; Cervical Intraepithelial Neoplasia/diagnosis ; Cervical Intraepithelial Neoplasia/epidemiology ; Cervical Intraepithelial Neoplasia/pathology ; Cross-Sectional Studies ; Female ; Humans ; Mexico/epidemiology ; Middle Aged ; Papanicolaou Test ; Prevalence ; Retrospective Studies ; Squamous Intraepithelial Lesions of the Cervix/diagnosis ; Squamous Intraepithelial Lesions of the Cervix/epidemiology ; Uterine Cervical Neoplasms/diagnosis ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/pathology ; Vaginal Smears
    Sprache Spanisch
    Erscheinungsdatum 2015
    Erscheinungsland Mexico
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 732133-8
    ISSN 0443-5117 ; 0484-7849
    ISSN 0443-5117 ; 0484-7849
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 2225: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Expression of transcription factor grainyhead-like 2 is diminished in cervical cancer.

    Torres-Reyes, Luis A / Alvarado-Ruiz, Liliana / Piña-Sánchez, Patricia / Martínez-Silva, María G / Ramos-Solano, Moisés / Olimón-Andalón, Vicente / Ortiz-Lazareno, Pablo C / Hernández-Flores, Georgina / Bravo-Cuellar, Alejandro / Aguilar-Lemarroy, Adriana / Jave-Suarez, Luis F

    International journal of clinical and experimental pathology

    2014  Band 7, Heft 11, Seite(n) 7409–7418

    Abstract: The transcription factor grainyhead-like 2 (GRHL2) is evolutionarily conserved in many different species, and is involved in morphogenesis, epithelial differentiation, and the control of the epithelial-mesenchymal transition. It has also recently been ... ...

    Abstract The transcription factor grainyhead-like 2 (GRHL2) is evolutionarily conserved in many different species, and is involved in morphogenesis, epithelial differentiation, and the control of the epithelial-mesenchymal transition. It has also recently been implicated in carcinogenesis, but its role in this remains controversial. Expression of GRHL2 has not previously been reported in cervical cancer, so the present study aimed to characterize GRHL2 expression in cervical cancer-derived cell lines (CCCLs) and cervical tissues with different grades of lesions. Microarray analysis found that the expression of 58 genes was down-regulated in CCCLs compared to HaCaT cells (non-tumorigenic human epithelial cell line). The expression of eight of these genes was validated by quantitative real-time PCR (qPCR), and GRHL2 was found to be the most down-regulated. Western blot assays corroborated that GRHL2 protein levels were strongly down-regulated in CCCLs. Cervical cells from women without cervical lesions were shown to express GRHL2, while immunohistochemistry found that positivity to GRHL2 decreased in cervical cancer tissues. In conclusion, a loss or strong reduction in GRHL2 expression appears to be a characteristic of cervical cancer, suggesting that GRHL2 down-regulation is a necessary step during cervical carcinogenesis. However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression.
    Mesh-Begriff(e) Carcinogenesis ; Cell Line, Tumor ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Down-Regulation ; Epithelial-Mesenchymal Transition ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/metabolism
    Chemische Substanzen DNA-Binding Proteins ; GRHL2 protein, human ; Transcription Factors
    Sprache Englisch
    Erscheinungsdatum 2014
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2418306-4
    ISSN 1936-2625 ; 1936-2625
    ISSN (online) 1936-2625
    ISSN 1936-2625
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang